FDA Grand Rounds

 

 

---

The FDA Grand Rounds is an educational presentation that is webcast monthly to highlight cutting-edge research underway across the Agency and its impact on protecting and advancing public health. Each session features an FDA scientist presenting on a key public health challenge and how FDA is applying science to its regulatory activities. The 45-minute educational presentation is followed by questions from the audience. You can also view the presentation under Past Grand Rounds following the live webcast. #FDAGrandRounds.

The next FDA Grand Rounds is scheduled for June 10, 2021. (Webcast only)

For more information and to register:

FDA's work with African Swine Fever from a policy and regulatory perspective 

Thursday, June 10, 2021
12:00 p.m. - 1:00 p.m. EST
Webcast Only

Presented by:

Jenny Murphy, MS
Deputy Director
Office of Surveillance and Compliance, CVM

Linda A. Benjamin, PhD
Supervisor, Animal Feed Safety Team
Division of Animal Feeds, CVM

About the Presentation:

African Swine Fever (ASF) is a highly contagious disease of swine (both farm-raised and wild) that causes significant economic losses to the swine industry in affected countries. The primary transmission of ASF is either pig-to-pig or through a pig consuming contaminated pork, but the virus can also be spread through ticks and inadvertently by humans. The ASF virus is considered a foreign animal disease (FAD) and the USDA has U.S. government lead for prevention, surveillance, and control. Data has emerged to show that animal food can also be a transmission vehicle, and FDA is the primary U.S. government responsible for the oversight of the animal food supply.

The FDA and USDA have been working collaboratively on thinking through the complexities of animal food as a vector for ASF transmission. The FDA is working to educate the pork and animal food industries on the importance of pre-market review for any substances utilized to mitigate the risk of ASF in animal food and has committed to expedited review of potential food additives used for this purpose. The FDA has developed an ASF response plan to identify critical activities needed to detect and respond to the presence of the virus in animal food to prevent further spread of the disease and to facilitate swift normalization for the production of and distribution of animal food in the event of an outbreak. The FDA is evaluating the feasibility of developing laboratory detection methods to enhance the biosecurity of imported animal food while maintaining the ability of U.S. grain producers to export their product.

Past Grand Rounds

2021

• Project Orbis: Global Collaborative Oncology Review Program
• Electrical Safety in CTP Regulated Products
• Studies of SARS-CoV-2 NSP1 and Envelope Protein
• Research and Development of Radioanalytical Capabilities for Detection of Radionuclides in Food
• FDA Grand Rounds: The CORE Network (or How I Learned to Love Lettuce…)

2020

• Assessment of Safety and Efficacy of Fecal Microbiota for Transplantation Products
• Facial Coverings During the COVID-19 Pandemic: How well do they flatten the curve?
• Bioequivalence of Complex Topical Generics: In Vitro and In Vivo
• Advancing the Science of Real-World Data to Address the COVID-19 Pandemic
• Nanotechnology: Over a Decade of Progress and Innovation at FDA
• A Pandemic and a Call to Action for One Health: The FDA One Health Initiative
• Artificial Intelligence for Regulatory Science Research
• Analysis of Per and Polyfluoroalkyl Substances (PFAS) in foods- Analytical method development, challenges and successes
• Modernization of Pharmaceutical Manufacturing through the Adoption of Advanced Technology
• Detection of Transmissible Spongiform Encephalopathy Agents in Biological Products Using Protein Aggregation Assays
• Quality Control: Stopping infections before they happen through safer endoscope reprocessing

2019

• Vet-LIRN – How FDA’s Network of Veterinary Diagnostic Laboratories advance animal food safety and public health by conducting outbreak investigations and monitoring resistance in animal pathogens
• Technical and Logistical Considerations for Examining FDA-Regulated Products at International Mail Facilities using Handheld and Field-Portable Analytical Devices

• Why FDA authorized the marketing of the IQOS heated tobacco product as “appropriate for the protection of the public health”

• Overview of FDA's Perinatal Health Center of Excellence: Development and Validation of Predictive Systems

• Cyclospora Cayetanensis: The Crossroads Between Scientific Advances and Knowledge Gaps 

• Gaining Insight into the Patient’s Experience by Harnessing the Power of Social Listening and FDA Archival Data 

• Uncertainty is the only certainty there is: Potential approaches for making public health decisions

• The VICTRE trial: an in-silico replica of a clinical trial for evaluating digital breast tomosynthesis as a replacement for full-field digital mammography

2018

• Jerky Pet Treats and illness in dogs:  a collaborative approach to investigating a mysterious outbreak
• Decomposition of Seafood Products by Mass Spectrometry with Sensory-Driven Predictive Modeling
• The Science to Inform a Tobacco Product Standard for the Level of Nicotine in Combusted Cigarettes
• Bisphenol A: Toxicology and Pharmacokenetic Data to Inform Ongoing Safety Assessments
• How Simulation Can Transform Regulatory Pathways
• FDA's Predictive Toxicology Roadmap: Implications and Opportunities for Stakeholders
• Are Stem Cells Ready for Prime Time? A Look at FDA Research Advances in Regenerative Medicine
• Ethnicity- and Gender-Related Differences in Alzheimer's Disease

2017

• Assessing the Safety and Effectiveness of New and Emerging Therapeutic Ultrasound Technologies
• Developing a Mechanistic Model-Based Approach to Assess Cardiac Safety of New Drugs
• Genome Trakr: How a Large Network of Sequencing Laboratories is Transforming Food Safety and Public Health
• Serious and Actionable Risks, Plus Disclosure: investigating an Alternative Approach for Presenting Risk Information in Prescription Drug TV Ads
• Vaccine adjuvants: New ways to evaluate their safety and effectiveness
• Developing Regulatory Methods for Characterizing Nanomaterials in FDA-Regulated Products

2016

• The Host Response to Whooping Cough Infection and Vaccination [Archived]
• Antibiotic resistance surveillance in the age of genomics: New answers to old questions [Archived]
• FDA Research into 3D Printing of its Regulated Products [Archived]
• Rapid Screening of Dietary Supplements for Undeclared Ingredients [Archived]
• Metabolomics and Proteomics Biomarkers: Discovery and Validation in Toxicity Studies [Archived]

Resources For You

• FDA's Predictive Toxicology Roadmap
• Don't Miss the CDC Public Health Grand Rounds